Possible involvement of RasGRP4 in leukemogenesis

Naoko Watanabe-Okochi, Toshihiko Oki, Yukiko Komeno, Naoko Kato, Koichiro Yuji, Ryoichi Ono, Yuka Harada, Hironori Harada, Yasuhide Hayashi, Hideaki Nakajima, Tetsuya Nosaka, Jiro Kitaura, Toshio Kitamura

研究成果: Article

12 引用 (Scopus)

抄録

It is now conceivable that leukemogenesis requires two types of mutations, class I and class II mutations. We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants. To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent. We identified RasGRP4, an activator of Ras, as a candidate for class I mutation from three of six patients (MDS/MPD = 1, MDS-RA = 1, MDS/AML = 2, CMMoL/AML = 1 and AML-M2 = 1). To investigate the potential roles of RasGRP4 in leukemogenesis, we tested its in vivo effect in a mouse bone marrow transplantation (BMT) model. C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia. To further examine if the combination of class I and class II mutations accelerated leukemic transformation, we performed a mouse BMT model in which both AML1 mutant (S291fsX300) and RasGRP4 were transduced into bone marrow cells. The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone. Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.

元の言語English
ページ(範囲)470-481
ページ数12
ジャーナルInternational Journal of Hematology
89
発行部数4
DOI
出版物ステータスPublished - 2009 5
外部発表Yes

Fingerprint

Mutation
Myelodysplastic Syndromes
T-Cell Leukemia
Myeloid Leukemia
Bone Marrow Transplantation
Bone Marrow Cells
Interleukin-3
Gene Library
Inbred C57BL Mouse
Organism Cloning
Leukemia
Bone Marrow
T-Lymphocytes
Cell Line
Genes

ASJC Scopus subject areas

  • Hematology

これを引用

Watanabe-Okochi, N., Oki, T., Komeno, Y., Kato, N., Yuji, K., Ono, R., ... Kitamura, T. (2009). Possible involvement of RasGRP4 in leukemogenesis. International Journal of Hematology, 89(4), 470-481. https://doi.org/10.1007/s12185-009-0299-0

Possible involvement of RasGRP4 in leukemogenesis. / Watanabe-Okochi, Naoko; Oki, Toshihiko; Komeno, Yukiko; Kato, Naoko; Yuji, Koichiro; Ono, Ryoichi; Harada, Yuka; Harada, Hironori; Hayashi, Yasuhide; Nakajima, Hideaki; Nosaka, Tetsuya; Kitaura, Jiro; Kitamura, Toshio.

:: International Journal of Hematology, 巻 89, 番号 4, 05.2009, p. 470-481.

研究成果: Article

Watanabe-Okochi, N, Oki, T, Komeno, Y, Kato, N, Yuji, K, Ono, R, Harada, Y, Harada, H, Hayashi, Y, Nakajima, H, Nosaka, T, Kitaura, J & Kitamura, T 2009, 'Possible involvement of RasGRP4 in leukemogenesis', International Journal of Hematology, 巻. 89, 番号 4, pp. 470-481. https://doi.org/10.1007/s12185-009-0299-0
Watanabe-Okochi N, Oki T, Komeno Y, Kato N, Yuji K, Ono R その他. Possible involvement of RasGRP4 in leukemogenesis. International Journal of Hematology. 2009 5;89(4):470-481. https://doi.org/10.1007/s12185-009-0299-0
Watanabe-Okochi, Naoko ; Oki, Toshihiko ; Komeno, Yukiko ; Kato, Naoko ; Yuji, Koichiro ; Ono, Ryoichi ; Harada, Yuka ; Harada, Hironori ; Hayashi, Yasuhide ; Nakajima, Hideaki ; Nosaka, Tetsuya ; Kitaura, Jiro ; Kitamura, Toshio. / Possible involvement of RasGRP4 in leukemogenesis. :: International Journal of Hematology. 2009 ; 巻 89, 番号 4. pp. 470-481.
@article{0a1ebd9271ce4dd1ae90a1b0fcf233af,
title = "Possible involvement of RasGRP4 in leukemogenesis",
abstract = "It is now conceivable that leukemogenesis requires two types of mutations, class I and class II mutations. We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants. To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent. We identified RasGRP4, an activator of Ras, as a candidate for class I mutation from three of six patients (MDS/MPD = 1, MDS-RA = 1, MDS/AML = 2, CMMoL/AML = 1 and AML-M2 = 1). To investigate the potential roles of RasGRP4 in leukemogenesis, we tested its in vivo effect in a mouse bone marrow transplantation (BMT) model. C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia. To further examine if the combination of class I and class II mutations accelerated leukemic transformation, we performed a mouse BMT model in which both AML1 mutant (S291fsX300) and RasGRP4 were transduced into bone marrow cells. The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone. Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.",
keywords = "AML1, CDNA library, Class I mutation, Leukemogenesis, RasGRP4",
author = "Naoko Watanabe-Okochi and Toshihiko Oki and Yukiko Komeno and Naoko Kato and Koichiro Yuji and Ryoichi Ono and Yuka Harada and Hironori Harada and Yasuhide Hayashi and Hideaki Nakajima and Tetsuya Nosaka and Jiro Kitaura and Toshio Kitamura",
year = "2009",
month = "5",
doi = "10.1007/s12185-009-0299-0",
language = "English",
volume = "89",
pages = "470--481",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Possible involvement of RasGRP4 in leukemogenesis

AU - Watanabe-Okochi, Naoko

AU - Oki, Toshihiko

AU - Komeno, Yukiko

AU - Kato, Naoko

AU - Yuji, Koichiro

AU - Ono, Ryoichi

AU - Harada, Yuka

AU - Harada, Hironori

AU - Hayashi, Yasuhide

AU - Nakajima, Hideaki

AU - Nosaka, Tetsuya

AU - Kitaura, Jiro

AU - Kitamura, Toshio

PY - 2009/5

Y1 - 2009/5

N2 - It is now conceivable that leukemogenesis requires two types of mutations, class I and class II mutations. We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants. To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent. We identified RasGRP4, an activator of Ras, as a candidate for class I mutation from three of six patients (MDS/MPD = 1, MDS-RA = 1, MDS/AML = 2, CMMoL/AML = 1 and AML-M2 = 1). To investigate the potential roles of RasGRP4 in leukemogenesis, we tested its in vivo effect in a mouse bone marrow transplantation (BMT) model. C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia. To further examine if the combination of class I and class II mutations accelerated leukemic transformation, we performed a mouse BMT model in which both AML1 mutant (S291fsX300) and RasGRP4 were transduced into bone marrow cells. The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone. Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.

AB - It is now conceivable that leukemogenesis requires two types of mutations, class I and class II mutations. We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants. To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent. We identified RasGRP4, an activator of Ras, as a candidate for class I mutation from three of six patients (MDS/MPD = 1, MDS-RA = 1, MDS/AML = 2, CMMoL/AML = 1 and AML-M2 = 1). To investigate the potential roles of RasGRP4 in leukemogenesis, we tested its in vivo effect in a mouse bone marrow transplantation (BMT) model. C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia. To further examine if the combination of class I and class II mutations accelerated leukemic transformation, we performed a mouse BMT model in which both AML1 mutant (S291fsX300) and RasGRP4 were transduced into bone marrow cells. The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone. Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.

KW - AML1

KW - CDNA library

KW - Class I mutation

KW - Leukemogenesis

KW - RasGRP4

UR - http://www.scopus.com/inward/record.url?scp=67449116506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449116506&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0299-0

DO - 10.1007/s12185-009-0299-0

M3 - Article

C2 - 19350351

AN - SCOPUS:67449116506

VL - 89

SP - 470

EP - 481

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -